LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute)(LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute))

概要

基本信息

药物类型

预防性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

感染皮肤和肌肉骨骼疾病其他疾病

在研适应症-

非在研适应症

皮肤利什曼病黑热病后皮肤利什曼原虫

原研机构

Access To Advanced Health Institute

在研机构-

非在研机构

Access To Advanced Health Institute

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute) 相关的临床试验

NCT01011309 / Completed临床2期IIT

A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in the Treatment of Patients With Cutaneous Leishmaniasis

The purpose of this study is to determine the efficacy, safety, and immunogenicity of an investigational vaccine being developed for the treatment of leishmaniasis, including cutaneous leishmaniasis (CL). The vaccine, identified as LEISH-F2 + MPL-SE, consists of a Leishmania protein (LEISH-F2) together with an adjuvant MPL-SE.

开始日期2009-10-01

申办/合作机构

Access To Advanced Health Institute

NCT00982774 / Completed临床1期IIT

Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in Combination With SSG in the Treatment of Patients With PKDL

A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of three injections of 10 µg LEISH-F2 + 25 µg MPL-SE given at 14-day intervals as an adjunct to standard chemotherapy with sodium stibogluconate (20 mg/kg/day for 40 days) in patients with PKDL.

开始日期2009-04-01

申办/合作机构

Access To Advanced Health Institute

100 项与 LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute) 相关的临床结果

登录后查看更多信息

100 项与 LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute) 相关的转化医学

登录后查看更多信息

100 项与 LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 LEISH-F2 + MPL-SE Vaccine(Access To Advanced Health Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
皮肤利什曼病	临床2期	秘鲁	Access To Advanced Health Institute	2009-10-01
黑热病后皮肤利什曼原虫	临床1期	苏丹	Access To Advanced Health Institute	2009-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01011309 (CTgov)	临床2期	皮肤利什曼病	45	MPL-SE (Immunotherapy v1.4/1.5)	窪觸築鹹鑰獵醖鬱鑰網(蓋構艱糧構艱窪願觸獵) = 膚製選鏇鹽獵夢鏇簾獵選鬱壓齋壓鹹願襯顧範 (醖繭憲構襯獵廠願鑰製, 蓋繭築顧積觸網窪簾獵 ~ 鏇範觸獵廠壓齋艱蓋憲) 更多	-	2013-11-18
				MPL-SE (Immunotherapy v1.6)	窪觸築鹹鑰獵醖鬱鑰網(蓋構艱糧構艱窪願觸獵) = 構餘夢醖繭淵鏇蓋艱鬱選鬱壓齋壓鹹願襯顧範 (醖繭憲構襯獵廠願鑰製, 夢廠獵獵遞網夢顧範網 ~ 鬱窪淵膚壓積鑰襯製鑰) 更多